Home | Contact
Deciphera in the News Deciphera logo
A pharmaceutical firm that moved to Lawrence from Cambridge, Mass., earlier this year has raised $15 million from private Kansas investors. Deciphera Pharmaceuticals, which is developing drugs to attack the molecular cause of Alzheimer's disease, rheumatoid arthritis, asthma and other diseases...”
- The Kansas City Star, December 19, 2003

Current Press Release

Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL

LAWRENCE, KS – Deciphera Pharmaceuticals LLC (Lawrence, KS USA) announces the initiation of their IND Phase 1 trial for DCC-2036 on March 25, 2009, at MD Anderson Cancer Center in Houston. This Phase 1 study will evaluate the safety and tolerability of once a day continuous oral dosing of DCC-2036, a BCR-ABL kinase inhibitor, in patients with treatment resistant or intolerant Philadelphia chromosome positive chronic myeloid leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) including patients with the T315I gatekeeper amino acid mutation, for whom there remains a significant unmet medical need. This study will also enroll patients at Tufts Medical Center in Boston.

DCC-2036 is a tyrosine kinase inhibitor that is based on a proprietary ‘kinase switch pocket’ platform which designs small molecule inhibitors to constrain otherwise activated kinases in inactive conformational states. This approach has particular application in oncology, where kinases become conformationally activated by mutation. In addition to its inhibition of BCR-ABL, DCC-2036 also potently inhibits TIE2, LYN, HCK and FLT3 kinases, all of which are relevant to the treatment of myleoproliferative diseases.

About Deciphera
Deciphera Pharmaceuticals, LLC was established in 2003 as a drug discovery and development company with the mission to design, optimize and introduce "best-in-class" small molecule switch inhibitors of protein kinases for human clinical trials and the global pharmaceutical marketplace through the use of its proprietary drug discovery technology platform, Phylomechanics. Deciphera's kinase inhibitors target the mechanisms that render kinases oncogenic, retain potency against gatekeeper mutations, and afford selectivity profiles not easily attained by other approaches. For more information, visit the Company’s website at www.deciphera.com.

Media/News

Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL

April 7, 2009

Lilly and Deciphera Pharmaceuticals Announce Licensing and Collaboration Agreement

October 3, 2008

KU to lease out vacant lab space for local expansion by Deciphera Pharmaceuticals

October 3, 2008

deCODE biostructures Renews Collaboration with Deciphera Pharmaceuticals, LLC.

March 24, 2008

Dr. James Bristol joins Deciphera Pharmaceuticals Board of Managers

August 30, 2007

Structures Speak Up

September 20, 2004 - Chemical & Engineering News

Lawrence life sciences firm gets $15M

December 18, 2003 - The Business Journal of Kansas City

Pharmaceutical firm to relocate to Lawrence

April 12, 2003 - Lawrence Journal-World

Lawrence lands drug firm

February 11, 2003 - Lawrence Journal-World


Deciphera Pharmaceuticals, LLC
643 Massachusetts
Suite 200
Lawrence, KS 66044

785 830-2100 phone
785 830-2150 fax
info@deciphera.com

Home | Senior Management | Platform | BCR-ABL | KIT | BRAF | News | Partners | Contact